Trial Profile

A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Cholangiocarcinoma
Focus Therapeutic Use
Acronyms SUN-CK; SUN-CK GERCOR

Most Recent Events

01 Aug 2025 Primary endpoint has been met. (Overall survival), According to Liver International.
01 Aug 2025 Results (n=53) evaluating efficacy and tolerability of sunitinib in patients with advanced ICC were published in the Liver International.
30 Jan 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com